Pharmaceutical Market Research
Annual revenues double in just one year
A boutique consulting firm, serving major pharmaceutical companies, was curious to see how a formal growth platform could help the company reach new clients and aggressively grow revenue.
Our lead consultant took on the role of VP of Business Development in order to build a successful growth initiative from the ground up. Within one year, the Company had acquired nine new major pharmaceutical company clients, annual revenue more than doubled, from $3MM to nearly $7MM. Employees went from 10 to almost 30. Within three years, the owner sold the business for over $25MM.
The first year of unplanned growth was destabilizing, but it did convince the owner to invest in a sustainable sales program. In the second year, two additional salespeople joined the team. We implemented a 3-year scalable sales plan to guide the business toward the owner’s eventual exit strategy.
The Challenge
As a boutique consulting firm serving major pharmaceutical companies, this company’s founder wanted to build a formal sales platform to help reach new clients and aggressively scale the company’s growth. The company had relied on the client relationships developed by the PhD staff, and while business was steady, it wasn’t growing fast enough. The owner felt the company was capable of much wider market penetration and much greater success.
The Solution
The 200% Company’s Lead Growth Consultant took on the role of VP of Business Development in order to build a successful growth initiative from the ground up. Within one year, the company had acquired nine new major pharmaceutical company clients, annual revenue more than doubled. The company became an even more dominant player in its industry and continued on its growth trajectory. With such rapid revenue growth and an enviable list of new pharmaceutical clients, this company was eventually sold to a global competitor for significantly greater value.
The 200% Result
9 major new Pharma clients in first year Annual revenues more than doubled Company sold for greater value